ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS ACHIEVE UNPRECEDENTED RESULTS IN FIRST-LINE HER2+ LOCALLY ADVANCED OR METASTATIC GEA INCLUDING MORE THAN TWO YEARS MEDIAN OVERALL SURVIVAL BENEFIT

Reuters · 4d ago

Please log in to view news